Literature DB >> 11106299

HIV dementia: the role of the basal ganglia and dopaminergic systems.

J R Berger1, G Arendt.   

Abstract

The clinical features of human immunodeficiency virus (HIV) dementia exhibit the hallmarks of a subcortical dementia. These features include psychomotor slowing, apathy, bradykinesia and altered posture and gait similar to those observed in advanced Parkinson's disease. The dementia has the hallmarks attributed to subcortical dementia. The exquisite sensitivity of many of these patients to dopamine receptor blockade suggested a profound and, perhaps, selective abnormality of striatal dopaminergic systems. Additional investigations, electrophysiological, pathological, virological, metabolic and radiological studies, indicate that the basal ganglia are a major target of HIV infection. In this review, we describe the evidence for involvement of basal ganglia and, in particular, the dopaminergic systems, in HIV dementia. We also suggest novel therapeutic strategies that may be beneficial in the treatment of this disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106299     DOI: 10.1177/026988110001400304

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  97 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

Review 2.  Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport.

Authors:  Italo Mocchetti; Alessia Bachis; Valeriya Avdoshina
Journal:  Neurotox Res       Date:  2011-09-27       Impact factor: 3.911

3.  Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains.

Authors:  Janelle M Silvers; Michael Y Aksenov; Marina V Aksenova; Jacob Beckley; Petra Olton; Charles F Mactutus; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

4.  Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.

Authors:  Italo Mocchetti; Alessia Bachis; Rachel L Nosheny; Gianluigi Tanda
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

5.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

6.  Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor.

Authors:  Janelle M Silvers; Marina V Aksenova; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurotoxicology       Date:  2007-07-22       Impact factor: 4.294

7.  [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein.

Authors:  Matthew Strauss; Bernadette O'Donovan; Yizhi Ma; Ziyu Xiao; Steven Lin; Michael T Bardo; Pavel I Ortinski; Jay P McLaughlin; Jun Zhu
Journal:  J Pharmacol Exp Ther       Date:  2020-05-27       Impact factor: 4.030

Review 8.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

9.  The Impact of Depressive Symptoms on Neuropsychological Performance Tests in HIV-Infected Individuals: A Study of the Hawaii Aging with HIV Cohort.

Authors:  Sheri M Shimizu; Dominic C Chow; Victor Valcour; Kamal Masaki; Beau Nakamoto; Kalpana J Kallianpur; Cecilia Shikuma
Journal:  World J AIDS       Date:  2011-12-01

Review 10.  Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease.

Authors:  S DeVaughn; E M Müller-Oehring; B Markey; H M Brontë-Stewart; T Schulte
Journal:  Neuropsychol Rev       Date:  2015-11-17       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.